Gentris Corporation and Quintiles Transnational Japan have collaborated on a partnership that is already delivering customers in Japan.

The firms announced Tuesday that Gentris had signed a preferred vendor and master services agreement with Quintiles Japan, a subsidiary of Quintiles Transnational in RTP.

The announcement comes after Gentris and Quintiles Japan signed several deals for pharmacogenomics projects with a number of Japanese pharmaceutical firms. Gentris had already signed deals with other firms in Japan and is considering opening an office there, according to a spokesman for the company.

Gentris will provide to Quintiles Japan services related to pharmacogenomics for testing and diagnostics. They include DNA isolation, purification, DNA banking, clinical genotyping and regulatory consulting.

“This agreement allows Quintiles Japan to provide its customers with pharmacogenomics services that we believe are unique to the Japanese market,” said Michael Murphy, chief executive officer of Gentris, in a statement.

Financial terms were not disclosed.

“We looked at several possible partner companies and made our selection based on Gentris’ leadership position in the quality and depth of services,” said Derek Winstanly, chairman of Quintiles Japan, in a statement. “Gentris exceeded our criteria on all fronts, and we look forward to a productive partnership with their team.”